Rhythm Pharmaceuticals (RYTM) EBIAT (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) reported EBIAT of -$55.6 million for Q1 2026, down 12.41% year-over-year from -$63.5 million in Q1 2025, and down 17.12% on a QoQ basis from -$47.5 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) has 11 years of EBIAT data on file, last reported at -$55.6 million in Q1 2026.
- Quarterly EBIAT fell 12.41% year-over-year to -$55.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$202.7 million (down 20.15% YoY) and the FY2025 annual result came in at -$196.5 million, up 24.58% from the prior year.
- EBIAT eased to -$55.6 million in Q1 2026 per RYTM's latest filing, from -$47.5 million in the prior quarter.
- Across five years, EBIAT topped out at -$32.3 million in Q2 2024 and bottomed at -$141.4 million in Q1 2024.
- The 5-year median for EBIAT is -$46.6 million (2025), against an average of -$51.7 million.
- The widest annual swing landed in 2022, when EBIAT tumbled 220.6%; it then jumped 64.99% in 2025.
- Tracing RYTM's EBIAT over 5 years: stood at -$42.5 million in 2022, then climbed by 2.02% to -$41.6 million in 2023, then dropped by 3.98% to -$43.3 million in 2024, then declined by 9.73% to -$47.5 million in 2025, then slipped by 17.12% to -$55.6 million in 2026.
- Per Business Quant, the three latest RYTM EBIAT figures stand at -$55.6 million (Q1 2026), -$47.5 million (Q4 2025), and -$52.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Rhythm Pharmaceuticals | 6.00 Bn | 5.66 Bn | 52.96 Mn | -55.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.64 Mn |
| Dec 31, 2025 | -47.51 Mn |
| Sep 30, 2025 | -52.90 Mn |
| Jun 30, 2025 | -46.63 Mn |
| Mar 31, 2025 | -49.50 Mn |
| Dec 31, 2024 | -43.29 Mn |
| Sep 30, 2024 | -43.64 Mn |
| Jun 30, 2024 | -32.26 Mn |
| Mar 31, 2024 | -141.37 Mn |
| Dec 31, 2023 | -41.63 Mn |
| Sep 30, 2023 | -44.16 Mn |
| Jun 30, 2023 | -46.70 Mn |
| Mar 31, 2023 | -52.18 Mn |
| Dec 31, 2022 | -42.49 Mn |
| Sep 30, 2022 | -40.86 Mn |
| Jun 30, 2022 | -45.00 Mn |
| Mar 31, 2022 | -52.76 Mn |
| Dec 31, 2021 | -50.86 Mn |
| Sep 30, 2021 | -35.11 Mn |
| Jun 30, 2021 | -35.39 Mn |
| Mar 31, 2021 | 43.75 Mn |
| Dec 31, 2020 | -34.90 Mn |
| Sep 30, 2020 | -33.82 Mn |
| Jun 30, 2020 | -31.12 Mn |
| Mar 31, 2020 | -34.16 Mn |
| Dec 31, 2019 | -32.96 Mn |
| Sep 30, 2019 | -36.00 Mn |
| Jun 30, 2019 | -42.80 Mn |
| Mar 31, 2019 | -28.97 Mn |
| Dec 31, 2018 | -25.51 Mn |
| Sep 30, 2018 | -17.69 Mn |
| Jun 30, 2018 | -14.41 Mn |
| Mar 31, 2018 | -16.46 Mn |
| Dec 31, 2017 | -10.53 Mn |
| Sep 30, 2017 | -10.02 Mn |
| Jun 30, 2017 | -6.80 Mn |
| Mar 31, 2017 | -6.36 Mn |
| Dec 31, 2016 | -8.37 Mn |
| Sep 30, 2016 | -6.39 Mn |